Bioxyne is an Australian publicly traded life sciences and consumer health products company and parent company of Breathe Life Sciences. For the last 15 years our unique formulations, healthcare solutions, and patient-focused approach has helped change millions of lives. Our goal is to be at the forefront of alternative medicines, researching and developing safer and more efficacious treatments, medicines, and health supplements to improve and prolong life.
Everything we do is underpinned by a strong clinical research and scientific foundation.
Bioxyne is owner of patented probiotic strain PCC® (Lactobacillus fermentum VRI-003), sold widely throughout the United States. PCC® has a superior ability to survive in the acid environment of the stomach and to colonise the intestinal tract. Through clinical trials our unique probiotic PCC® formulation has been proven to boost immune and gastrointestinal health. PCC® and our other probiotic formulations are manufactured by Chr. Hansen, a global leader in the manufacturing of probiotics and other dietary supplement products for the food, health, pharmaceutical and agricultural businesses.
In May 2023 Bioxyne acquired Breathe Life Sciences Pty Ltd, an Australian pharmaceuticals company licensed by the Department of Health and Aged Care, and the Queensland government to import, export, manufacture and supply scheduled drugs including medicinal cannabis (S3, S4, S8). The Breathe Life Sciences group of companies operates in Australia (parent company), Japan, United Kingdom, Czechia, Switzerland, France, Germany, and the United States where it is a market leader in the production and supply of starting materials, extracts, and white label manufactured wellness, supplement, CBD, mushrooms, nootropic and skincare products.
WHERE ARE WE
Our mission is to be a global leader in the manufacture and supply of novel medicines and healthcare solutions, pioneering new age treatments and cures for both mental and physical disease, contributing to the pharmacopeia and delivering the highest quality standards for health products and novel medicines to our patients and customers worldwide.
For the span of human history, people have not only used plants to derive basic nutrients, but have also use them in various ways to treat, prevent , and alleviate symptoms of many common diseases and ailments. As science has advanced our ability to identify the underlying agents of these benefits, plant-based medicine has evolved into a multi-billion dollar industry. Whether derived directly from plant material, or through the production of synthetic analogues in a laboratory, many of the key compounds and metabolites found in plants have given us everything from aspirin (acetylsalicylic acid) to some of the most powerful opiates. So it is no surprise that many of our modern-day pharmaceuticals are derived from plants. It is also likely that we have only just scratched the surface of nature’s pharmacopeia, with many plant compounds, and their potential roles in human health and nutrition yet to be discovered.
Many of these compounds, and, in some cases, the plants or fungi that produce them, have often been restricted in their use, or made completely illicit given their potency and psychotropic properties. The unintended, and unfortunate consequences of making plants and fungus-derived compounds illegal was that the wide range of highly beneficial compounds produced by them were excluded from human consumption because of their association with their psychotropic effects.
It is only in the last decade that legislation has allowed the study and human use of these compounds in treating disease. We are at the forefront of change and opportunity in this healthcare revolution.